Join the 'Reversal of Nondepolarizing Muscle Relaxants' group to help and get support from people like you.
Reversal of Nondepolarizing Muscle Relaxants News
Posted 17 Dec 2015 by Drugs.com
December 15, 2015 – The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults. Rocuronium bromide and vecuronium bromide are neuromuscular blocking drugs that cause temporary paralysis by interfering with the transmission of nerve impulses to the muscle and are used to paralyze the vocal cords when patients require an artificial airway or breathing tube for surgery, a process called tracheal intubation. They can also be used to prevent patients from moving during surgery while they are receiving general anesthesia. Neuromuscular blocking drugs are also sometimes used to prevent the body from breathing automatically when a patient has to be placed on a ventilator. "Bridion provides a new treatment ... Read more
Posted 16 Dec 2015 by Drugs.com
TUESDAY, Dec. 15, 2015 – Bridion (sugammadex) has been approved by the U.S. Food and Drug Administration to reverse the effects of medications that are used to paralyze the vocal chords during certain surgical procedures. Rocuronium bromide and vecuronium bromide are prescribed when surgeons use an artificial airway or breathing tube, a process called tracheal intubation, the FDA said Tuesday in a news release. These so-called "neuromuscular blocking drugs" also may be used to prevent a person receiving general anesthesia from moving during surgery, or to prevent a person from breathing automatically while on a ventilator, the FDA added. In clinical studies involving more than 450 people, Bridion was evaluated in reversing the effects of these drugs. Most people who received Bridion recovered within 5 minutes of its use, the FDA said. However, the agency warned of the possibility of ... Read more
Posted 5 Jun 2013 by Drugs.com
LYON, FRANCE – (Marketwire) – 06/03/2013 – Flamel Technologies today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for Bloxiverz (neostigmine methylsulfate), a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Flamel expects to launch Bloxiverz in July 2013 in 0.5 and 1.0 mg/mL strengths. "We are extremely excited and pleased to receive this FDA approval for Bloxiverz, the first product from the portfolio of Éclat products acquired in March 2012," said Mike Anderson, Chief Executive Officer of Flamel. Bloxiverz is the first FDA-approved version of neostigmine, even though other versions of neostigmine have been on the market as unapproved, grandfathered products under the Food, Drug and Cosmetic Act of 1938. Today, ... Read more